Tyra Biosciences dosed first patient in SURF201 for TYRA-200; TYRA-300 Part A clears dose cohorts; plans ACH IND H2 2024

Tyra Biosciences, Inc.

First patient dosed in SURF201 Phase 1 study of TYRA-200 for FGFR2-altered cholangiocarcinoma and advanced solid tumors.
SURF301 Part A dose escalation cleared multiple cohorts above anticipated dose for Phase 2 achondroplasia study.
Expansion cohorts in SURF301 Part B at dose levels anticipated for oncology evaluation.
Tyra plans to submit initial SURF301 Phase 1 results for a scientific congress in 2024.
Company plans to submit IND for TYRA-300 in pediatric achondroplasia in H2 2024, starting with ages 5-12.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.